Teva Will Assume Azilect Marketing From Eisai
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva will assume full U.S. marketing responsibilities for Azilect (rasagiline) for Parkinson's disease following dissolution of its co-development agreement with Eisai, the companies announced July 12